{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:32:31Z","timestamp":1794879151807,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["1106078"],"award-info":[{"award-number":["1106078"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Oral cholera vaccines (OCV) have been recommended as additional measures for the prevention of cholera. However, little is known about the cost-effectiveness of OCV use in sub-Saharan Africa, particularly in reactive outbreak contexts. This study aimed to investigate the cost-effectiveness of the use of OCV Shanchol in response to a cholera outbreak in the Lake Chilwa area, Malawi.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Excel-based Vaccine Introduction Cost-Effectiveness model was used to assess the cost-effectiveness ratios with and without indirect protection. Model input parameters were obtained from cost evaluations and epidemiological studies conducted in Malawi and published literature. One-way sensitivity and threshold analyses of cost-effectiveness ratios were performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with the reference scenario i.e. treatment of cholera cases, the immunization campaign would have prevented 636 and 1 020 cases of cholera without and with indirect protection, respectively. The cost-effectiveness ratios were US$19 212 per death, US$500 per case, and US$738 per DALY averted without indirect protection. They were US$10 165 per death, US$264 per case, and US$391 per DALY averted with indirect protection. The net cost per DALY averted was sensitive to four input parameters, including case fatality rate, duration of immunity (vaccine\u2019s protective duration), discount rate and cholera incidence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Relative to the Malawi gross domestic product per capita, the reactive OCV campaign represented a cost-effective intervention, particularly when considering indirect vaccine effects. Results will need to be assessed in other settings, e.g., during campaigns implemented directly by the Ministry of Health rather than by international partners.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12962-021-00270-y","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T12:03:23Z","timestamp":1615377803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost-effectiveness of a reactive oral cholera immunization campaign using Shanchol\u2122 in Malawi"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1956-6971","authenticated-orcid":false,"given":"Patrick G.","family":"Ilboudo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford D.","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bagrey","family":"Ngwira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Cavailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bernard","family":"Le Gargasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"issue":"2","key":"270_CR1","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1371\/journal.pntd.0000173","volume":"2","author":"JL Deen","year":"2008","unstructured":"Deen JL, von Seidlein L, Sur D, Agtini M, Lucas ME, Lopez AL, et al. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis. 2008;2(2):e173.","journal-title":"PLoS Negl Trop Dis"},{"key":"270_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1472-698X-9-8","volume":"9","author":"JM Kirigia","year":"2009","unstructured":"Kirigia JM, Sambo LG, Yokouide A, Soumbey-Alley E, Muthuri LK, Kirigia DG. Economic burden of cholera in the WHO African region. BMC international health and human rights. 2009;9:8.","journal-title":"BMC international health and human rights"},{"key":"270_CR3","unstructured":"WHO. Cholera vaccines: WHO position paper. 2010 Contract No.: 85."},{"key":"270_CR4","first-page":"231","volume":"379","author":"J Clemens","year":"2014","unstructured":"Clemens J, Holmgren J. When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks? Curr Top Microbiol Immunol. 2014;379:231\u201358.","journal-title":"Curr Top Microbiol Immunol"},{"key":"270_CR5","unstructured":"WHO. Prevention and control of cholera outbreaks: WHO policy and recommendations. Global Task Force on Cholera Control. 2011."},{"key":"270_CR6","unstructured":"WHO\/UNICEF. Progress on Drinking Water and Sanitation: 2012 Update. 2012."},{"key":"270_CR7","unstructured":"WHO. WHO Prequalified Vaccines Geneva, Switzerland: WHO; 2016 [12\/13\/2016]. https:\/\/extranet.who.int\/gavi\/PQ_Web\/."},{"issue":"10","key":"270_CR8","doi-asserted-by":"publisher","first-page":"e1289","DOI":"10.1371\/journal.pntd.0001289","volume":"5","author":"D Sur","year":"2011","unstructured":"Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, et al. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis. 2011;5(10):e1289.","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"270_CR9","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S1473-3099(13)70273-1","volume":"13","author":"SK Bhattacharya","year":"2013","unstructured":"Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2013;13(12):1050\u20136.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"270_CR10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2471\/BLT.14.139949","volume":"92","author":"S Martin","year":"2014","unstructured":"Martin S, Lopez AL, Bellos A, Deen J, Ali M, Alberti K, et al. Post-licensure deployment of oral cholera vaccines: a systematic review. Bull World Health Organ. 2014;92(12):881\u201393.","journal-title":"Bull World Health Organ"},{"issue":"9","key":"270_CR11","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1128\/CVI.00378-14","volume":"21","author":"S Kabir","year":"2014","unstructured":"Kabir S. Critical analysis of compositions and protective efficacies of oral killed cholera vaccines. Clinical Vaccine Immunol. 2014;21(9):1195\u2013205.","journal-title":"Clinical Vaccine Immunol"},{"issue":"48","key":"270_CR12","doi-asserted-by":"publisher","first-page":"6878","DOI":"10.1016\/j.vaccine.2015.07.045","volume":"33","author":"M Ali","year":"2015","unstructured":"Ali M, You YA, Kanungo S, Manna B, Deen JL, Lopez AL, et al. Assessing different measures of population-level vaccine protection using a case-control study. Vaccine. 2015;33(48):6878\u201383.","journal-title":"Vaccine"},{"issue":"3","key":"270_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/21645515.2016.1245250","volume":"13","author":"SN Desai","year":"2017","unstructured":"Desai SN, Pezzoli L, Alberti KP, Martin S, Costa A, Perea W, et al. Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era. Human Vaccines Immunotherapeutics. 2017;13(3):579\u201387.","journal-title":"Human Vaccines Immunotherapeutics"},{"issue":"1","key":"270_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1186\/s12879-017-2885-8","volume":"17","author":"PG Ilboudo","year":"2017","unstructured":"Ilboudo PG, Le Gargasson JB. Delivery cost analysis of a reactive mass cholera vaccination campaign: a case study of Shanchol vaccine use in Lake Chilwa, Malawi. BMC Infect Dis. 2017;17(1):779.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"270_CR15","doi-asserted-by":"publisher","first-page":"e0185041","DOI":"10.1371\/journal.pone.0185041","volume":"12","author":"PG Ilboudo","year":"2017","unstructured":"Ilboudo PG, Huang XX, Ngwira B, Mwanyungwe A, Mogasale V, Mengel MA, et al. Cost-of-illness of cholera to households and health facilities in rural Malawi. PLoS ONE. 2017;12(9):e0185041.","journal-title":"PLoS ONE"},{"key":"270_CR16","unstructured":"Malawi National Statistical Office. GeoHive - Malawi population statistics Malawi: Geohive; 2016 [11\/30\/2016]. http:\/\/www.geohive.com\/cntry\/malawi.aspx."},{"issue":"2","key":"270_CR17","first-page":"29","volume":"24","author":"A Khonje","year":"2012","unstructured":"Khonje A, Metcalf CA, Diggle E, Mlozowa D, Jere C, Akesson A, et al. Cholera outbreak in districts around Lake Chilwa, Malawi: lessons learned. Malawi Medical J. 2012;24(2):29\u201333.","journal-title":"Malawi Medical J"},{"key":"270_CR18","first-page":"2016","volume-title":"monitoring health for the SDGs, sustainable development goals","author":"WHO. World health statistics","year":"2016","unstructured":"WHO. World health statistics. monitoring health for the SDGs, sustainable development goals. Geneva, Switzerland: WHO; 2016. p. 2016."},{"key":"270_CR19","unstructured":"OANDA. 1996\u20132016 OANDA 2016 [17\/11\/2016]. https:\/\/www.oanda.com\/lang\/fr\/."},{"key":"270_CR20","volume-title":"Vaccine Introduction Cost-Effectiveness Calculator (VICE)","author":"C Troeger","year":"2014","unstructured":"Troeger C, Chao D, Sack D. Vaccine Introduction Cost-Effectiveness Calculator (VICE). USA: Johns Hopkins Bloomberg School of Public Health; 2014."},{"issue":"6","key":"270_CR21","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.1524-4733.2009.00562.x","volume":"12","author":"Jeuland M, Cook J, Poulos C, Clemens J, Whittington D, Group DCES","year":"2009","unstructured":"Jeuland M, Cook J, Poulos C, Clemens J, Whittington D, Group DCES. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value In Health J Int Society Pharmacoeconomics Outcomes Res. 2009;12(6):899\u2013908.","journal-title":"Value In Health J Int Society Pharmacoeconomics Outcomes Res"},{"issue":"6","key":"270_CR22","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.4269\/ajtmh.14-0159","volume":"91","author":"C Troeger","year":"2014","unstructured":"Troeger C, Sack DA, Chao DL. Evaluation of targeted mass cholera vaccination strategies in Bangladesh: a demonstration of a new cost-effectiveness calculator. Am J Trop Med Hyg. 2014;91(6):1181\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"270_CR23","unstructured":"M\u00e9decins Sans Fronti\u00e8res. Cholera outbreak response Lake Chilwa south-east Region districts of Machinga, Phalombe and Zomba. 2016."},{"issue":"11","key":"270_CR24","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1371\/journal.pmed.0040336","volume":"4","author":"IM Longini Jr","year":"2007","unstructured":"Longini IM Jr, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. Controlling endemic cholera with oral vaccines. PLoS Med. 2007;4(11):e336.","journal-title":"PLoS Med"},{"issue":"1","key":"270_CR25","first-page":"1","volume":"24","author":"DA Sack","year":"2006","unstructured":"Sack DA. Herd protection and herd amplification in cholera. J Health Popul Nutr. 2006;24(1):1\u20135.","journal-title":"J Health Popul Nutr"},{"issue":"8","key":"270_CR26","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/cid\/cit009","volume":"56","author":"M Ali","year":"2013","unstructured":"Ali M, Sur D, You YA, Kanungo S, Sah B, Manna B, et al. Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India. Clinical infectious diseases Official Publication Infectious Diseases Society America. 2013;56(8):1123\u201331.","journal-title":"Clinical infectious diseases Official Publication Infectious Diseases Society America"},{"issue":"12","key":"270_CR27","doi-asserted-by":"publisher","first-page":"e0005124","DOI":"10.1371\/journal.pntd.0005124","volume":"10","author":"V Mogasale","year":"2016","unstructured":"Mogasale V, Ramani E, Wee H, Kim JH. Oral Cholera vaccination delivery cost in low- and middle-income countries: an analysis based on systematic review. PLoS Negl Trop Dis. 2016;10(12):e0005124.","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"270_CR28","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1017\/S0950268811000513","volume":"140","author":"C Poulos","year":"2012","unstructured":"Poulos C, Riewpaiboon A, Stewart JF, Clemens J, Guh S, Agtini M, et al. Costs of illness due to endemic cholera. Epidemiol Infect. 2012;140(3):500\u20139.","journal-title":"Epidemiol Infect"},{"issue":"10","key":"270_CR29","doi-asserted-by":"publisher","first-page":"e1844","DOI":"10.1371\/journal.pntd.0001844","volume":"6","author":"C Schaetti","year":"2012","unstructured":"Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, et al. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar. PLoS Negl Trop Dis. 2012;6(10):e1844.","journal-title":"PLoS Negl Trop Dis"},{"key":"270_CR30","unstructured":"World Health Organization, editor. WHO guide for standardization of economic evaluations of immunization programmes. Geneva: WHO; 2008."},{"key":"270_CR31","unstructured":"World Bank. Workd http:\/\/data.worldbank.org\/."},{"key":"270_CR32","unstructured":"Sauvageot D, Munier A, Saussier C. Impact Study of Oral Cholera Vaccine Campaign, Machinga and Zomba Districts, Malawi: re-analysis of cholera incidence data. 2017."},{"key":"270_CR33","volume-title":"Cholera in Malawi","author":"M M'Bangombe","year":"2017","unstructured":"M\u2019Bangombe M. Cholera in Malawi. Malawi: Blantyre; 2017."},{"key":"270_CR34","unstructured":"MSF. Oral cholera vaccintion campaign on Lake Chilwa and its three districts (Machinga, Phalombe, Zomba), Malawi. Paris, France: MSF, 2016."},{"issue":"10","key":"270_CR35","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(17)30359-6","volume":"17","author":"Q Bi","year":"2017","unstructured":"Bi Q, Ferreras E, Pezzoli L, Legros D, Ivers LC, Date K, et al. Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(10):1080\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"9859","key":"270_CR36","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","volume":"380","author":"JA Salomon","year":"2012","unstructured":"Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129\u201343.","journal-title":"Lancet"},{"key":"270_CR37","unstructured":"WHO. Life expectancy at birth (years), 2000\u20132015. Both sexes: 2015 Geneva, Switzerland2016 [cited 2017 22\/02]. http:\/\/gamapserver.who.int\/gho\/interactive_charts\/mbd\/life_expectancy\/atlas.html."},{"issue":"46","key":"270_CR38","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1016\/j.vaccine.2015.09.088","volume":"33","author":"HK Smalley","year":"2015","unstructured":"Smalley HK, Keskinocak P, Swann J, Hinman A. Optimized oral cholera vaccine distribution strategies to minimize disease incidence: A mixed integer programming model and analysis of a Bangladesh scenario. Vaccine. 2015;33(46):6218\u201323.","journal-title":"Vaccine"},{"key":"270_CR39","unstructured":"Levin A, Maskery B, DeRoeck D, al. e. An investment case for the accelerated introduction of oral cholera vaccines. . International Vaccine Institute, 2012."},{"key":"270_CR40","unstructured":"Kim SY, Choi Y, Mason PR, Rusakaniko S, Goldie SJ. Potential impact of reactive vaccination in controlling cholera outbreaks: an exploratory analysis using a Zimbabwean experience. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2011;101(9):659\u201364."},{"issue":"1","key":"270_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-7622-11-1","volume":"11","author":"IC Fung","year":"2014","unstructured":"Fung IC. Cholera transmission dynamic models for public health practitioners. Emerging Themes Epidemiol. 2014;11(1):1.","journal-title":"Emerging Themes Epidemiol"},{"issue":"4","key":"270_CR42","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/S2214-109X(16)00037-1","volume":"4","author":"SN Desai","year":"2016","unstructured":"Desai SN, Pezzoli L, Martin S, Costa A, Rodriguez C, Legros D, et al. A second affordable oral cholera vaccine: implications for the global vaccine stockpile. Lancet Global health. 2016;4(4):e223\u20134.","journal-title":"Lancet Global health"},{"issue":"5","key":"270_CR43","doi-asserted-by":"publisher","first-page":"e0215972","DOI":"10.1371\/journal.pone.0215972","volume":"14","author":"T Tembo","year":"2019","unstructured":"Tembo T, Simuyandi M, Chiyenu K, Sharma A, Chilyabanyama ON, Mbwili-Muleya C, et al. Evaluating the costs of cholera illness and cost-effectiveness of a single dose oral vaccination campaign in Lusaka, Zambia. PLoS ONE. 2019;14(5):e0215972.","journal-title":"PLoS ONE"},{"issue":"11","key":"270_CR44","doi-asserted-by":"publisher","first-page":"e856","DOI":"10.1016\/S2214-109X(16)30211-X","volume":"4","author":"AS Azman","year":"2016","unstructured":"Azman AS, Parker LA, Rumunu J, Tadesse F, Grandesso F, Deng LL, et al. Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. Lancet Global health. 2016;4(11):e856\u201363.","journal-title":"Lancet Global health"},{"issue":"6","key":"270_CR45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMc1711583","volume":"378","author":"E Ferreras","year":"2018","unstructured":"Ferreras E, Chizema-Kawesha E, Blake A, Chewe O, Mwaba J, Zulu G, et al. Single-Dose Cholera Vaccine in Response to an Outbreak in Zambia. N Engl J Med. 2018;378(6):577\u20139.","journal-title":"N Engl J Med"},{"issue":"18","key":"270_CR46","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1510330","volume":"374","author":"F Qadri","year":"2016","unstructured":"Qadri F, Wierzba TF, Ali M, Chowdhury F, Khan AI, Saha A, et al. Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh. N Engl J Med. 2016;374(18):1723\u201332.","journal-title":"N Engl J Med"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-021-00270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12962-021-00270-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-021-00270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T12:15:13Z","timestamp":1615378513000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-021-00270-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1186\/s12962-021-00270-y","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The overall study protocol received clearance from the National Health Sciences Research Committee (NHSRC) of the Ministry of Health in Malawi (approval number: NHSRC # 16\/3\/1559). Secondary data were used for the cost-effectiveness modelling.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PGI, JBL, MAM, PC and BDG work for AMP which receives unrestricted funding from Sanofi Pasteur and grant-specific support from Crucell, Sanofi Pasteur, Pfizer, Merck, and GlaxoSmithKline.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}